WRUR 88.5 Different Radio

Jon Hamilton

Jon Hamilton is a correspondent for NPR's Science Desk. Currently he focuses on neuroscience and health risks.

In 2014, Hamilton went to Liberia as part of the NPR team that covered Ebola. The team received a Peabody Award for its coverage.

Following the 2011 earthquake and tsunami in Japan, Hamilton was part of NPR's team of science reporters and editors who went to Japan to cover the crisis at the Fukushima Dai-ichi nuclear power plant.

Hamilton contributed several pieces to the Science Desk series "The Human Edge," which looked at what makes people the most versatile and powerful species on Earth. His reporting explained how humans use stories, how the highly evolved human brain is made from primitive parts, and what autism reveals about humans' social brains.

In 2009, Hamilton received the Michael E. DeBakey Journalism Award for his piece on the neuroscience behind treating autism.

Before joining NPR in 1998, Hamilton was a media fellow with the Henry J. Kaiser Family Foundation studying health policy issues. He reported on states that have improved their Medicaid programs for the poor by enrolling beneficiaries in private HMOs.

From 1995-1997, Hamilton wrote on health and medical topics as a freelance writer, after having been a medical reporter for both The Commercial Appeal and Physician's Weekly.

Hamilton graduated with honors from Oberlin College in Ohio with a Bachelor of Arts in English. As a student, he was the editor of the Oberlin Review student newspaper. He earned his master's degree in journalism from Columbia University, where he graduated with honors. During his time at Columbia, Hamilton was awarded the Baker Prize for magazine writing and earned a Sherwood traveling fellowship.

Out-of-body experiences are all about rhythm, a team reported Wednesday in the journal Nature.

In mice and one person, scientists were able to reproduce the altered state often associated with ketamine by inducing certain brain cells to fire together in a slow, rhythmic fashion.

Some mighty mice have overcome one of the major obstacles to interplanetary space flight: muscle and bone loss.

The mice got a drug that prevented the usual decreases in muscle and bone mass during a month on the International Space Station, a team reports in the journal Proceedings of the National Academy of Sciences.

Copyright 2020 NPR. To see more, visit https://www.npr.org.

AILSA CHANG, HOST:

A combination of two experimental drugs appears to slow the decline of patients with amyotrophic lateral sclerosis, an illness often known as ALS or Lou Gehrig's disease.

A six-month study of 137 patients with a fast-progressing form of the disease found that those who got daily doses of a two-drug combination called AMX0035 scored several points higher on a standard measure of function, a team reports in the Sept. 3 issue of The New England Journal of Medicine.

COVID-19 forced Keriann Wilmot's son to trade his classroom for a computer. It was a tough transition for a 10-year-old with attention deficit hyperactivity disorder.

"It was a different environment for him," Wilmot says. "He wasn't used to this kind of work from school coming in the format of an email in his Chromebook every single day."

The Food and Drug Administration has approved a variant of the anesthetic and party drug ketamine for suicidal patients with major depression.

The drug is a nasal spray called Spravato and it contains esketamine, a chemical cousin of ketamine.

This is the story of a fatal genetic disease, a tenacious scientist and a family that never lost hope.

Conner Curran was 4 years old when he was diagnosed with Duchenne muscular dystrophy, a genetic disease that causes muscles to waste away.

Conner's mother, Jessica Curran, remembers some advice she got from the doctor who made that 2015 diagnosis: "Take your son home, love him, take him on trips while he's walking, give him a good life and enjoy him because there are really not many options right now."

For years, public health officials have been trying to dispel the myth that people who get a flu shot are more likely to get Alzheimer's disease.

They are not. And now there is evidence that vaccines that protect against the flu and pneumonia may actually protect people from Alzheimer's, too.

The same process that causes dew drops to form on a blade of grass appears to play an important role in Alzheimer's disease and other brain diseases.

Scientists are monitoring the virus that causes COVID-19 for genetic changes that could make a vaccine ineffective. But so far, they're not seeing any.

Pages